Analyst Etzer Darout of BMO Capital maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of $89.00.

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis. So, if you’re still on the fence about whether GSK plc is a buy, sell or ...

Glaxosmithkline Pharmaceuticals Ltd share ... All timestamps reflected here are in IST (Indian Standard Time). Stock Analysis section has been sourced from the mentioned partners.

Here are some quick facts to get you started if you are interested in the stock: GSK has logged a 1.2% 52 week change ... The company's current operating margins stand at 22.2% The above analysis is ...

Fundsmith Equity fell off Interactive Investor's most-bought list as tech funds begin to drop in popularity among retail ...

Welcome to the Moderna third quarter 2024 conference call. [Operator instructions] Please be advised today's conference is ...

With a net cash position (including investments) over more than 10 years, Nabtesco has maintained a healthy balance sheet, in our view. As of fiscal 2023, net debt/EBITDA is at minus 1.1 and we expect ...

Not too long ago, pharmaceutical giant Astrazeneca reached a £200bn valuation—one of only a few London-listed FTSE 100 ...

In its third quarter results of 2024, pharmaceutical giant GSK confirmed it would pay a quarterly dividend of 15 pence. However, Morningstar analyst Christopher Johnson says he believes that GSK’s ...